<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Podocalyxin-like 1 (PODXL) is a cell-<z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> <z:chebi fb="2" ids="17089">glycoprotein</z:chebi> and stem cell marker that has been associated with an aggressive <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> phenotype and poor prognosis in several forms of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>In this study, we investigated the prognostic impact of PODXL expression in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Using tissue microarrays and immunohistochemistry, PODXL expression was evaluated in 536 incident <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cases from a prospective, population-based cohort study </plain></SENT>
<SENT sid="3" pm="."><plain>Kaplan-Meier analysis and Cox proportional hazards modelling were used to assess the impact of PODXL expression on <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-specific survival (CSS) and overall survival (OS) </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: High PODXL expression was significantly associated with unfavourable clinicopathological characteristics, a shorter CSS (hazard ratio (HR)=1.98; 95% confidence interval (CI) 1.38-2.84, P&lt;0.001) and 5-year OS (HR=1.85; 95% CI 1.29-2.64, P=0.001); the latter remaining significant in multivariate analysis (HR=1.52; 95% CI 1.03-2.25, P=0.036) </plain></SENT>
<SENT sid="5" pm="."><plain>In addition, in curatively resected stage III (T1-4, N1-2, M0) patients (n=122) with <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> with high PODXL expression, a significant benefit from adjuvant chemotherapy was demonstrated (p(interaction) =0.004 for CSS and 0.015 for 5-year OS in multivariate analysis) </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSION: Podocalyxin-like 1 expression is an independent factor of poor prognosis in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Our results also suggest that PODXL may be a useful marker to stratify patients for adjuvant chemotherapy </plain></SENT>
</text></document>